Biocompatible materials capable of controlling crystallization in different chemical environments, while carrying large amounts of active pharmaceutical ingredients (APIs), are highly desirable for industrial practices. A method for controlling crystallization is nucleation, a critical step in the crystallization process, where heteronucleant materials are specifically designed to influence selective interactions with target compounds. In industrial practice, compounds to be crystalized are diverse in chemical structure and in physical properties, such as solubility. Therefore, designing biocompatible heteronucleants capable controlling crystallization and carrying vast amounts of pharmaceutical compounds in diverse environments is a challenge. A promising material for heteronucleant design is synthetic poly (ethylglycol) (PEG) an exceptional material for controlling nucleation. However, PEG hydrogels are prepared by free radical polymerization, a process generally avoided in the pharmaceutical industry.
This invention involves designing a nanostructure and chemical makeup of a biocompatible alginate hydrogel capable of controlling nucleation from compounds with different polarities and chemical properties.